Independent. No tobacco money. No corporate fluff.THU, OCT 8

PouchDaily

The daily pulse of the nicotine pouch market

Science
US

Researchers read 73 new nicotine pouch studies. Here's what the big picture looks like now

An NIH- and FDA-funded team pulled 73 new studies into one review: youth use creeping up, adult use low, sales tripling — and stronger pouches delivering nicotine faster than cigarettes.

PouchDaily Desk·
researchsciencenicotine deliveryyouth useUS

The research base on nicotine pouches just got its biggest stocktake yet. An updated scoping review published in Nicotine & Tobacco Research on September 6, 2026 pulled in 73 new empirical studies since the same team's previous review — and the picture it paints is more detailed than the one regulators were working from when the rules started being written.

The team is heavyweight and publicly funded, which matters for how the findings land: Nargiz Travis, Kenneth Warner, Jamie Hartmann-Boyce, Maciej Goniewicz and colleagues from Georgetown, Michigan, UMass Amherst and Roswell Park, with funding from the NIH and FDA. The updated search covers evidence through September 2025. Most of the 73 new studies were conducted in the US; 12 were industry-funded.

What the numbers say

The review's abstract is unusually specific, and the specifics cut in several directions at once:

  • Youth use is rising, slowly. Nationally representative US surveys put current youth use between 1.8% (NYTS) and 2.6% (Monitoring the Future, 10th and 12th graders) in 2024.
  • Adult use remains low. 0.4%–0.8% of US adults used pouches in 2022–2023, concentrated among ages 18–44 and current tobacco users.
  • Sales have exploded. US pouch sales more than tripled between 2021 and 2024.
  • Marketing is a red flag. The review says strategies increasingly emphasize potentially youth-appealing claims, with online and social media as key promotional channels.

The delivery finding regulators will read twice

The most consequential line for policy is this: pouches generally contain a higher proportion of freebase nicotine than other oral products, and nicotine uptake from stronger pouches (6 mg and above) typically exceeds that from cigarettes in adult smokers — even though pouches consistently score lower than cigarettes on positive subjective ratings. In plain terms, a strong pouch can deliver nicotine faster and harder than a cigarette, without the ritual that keeps consumption self-limiting.

At the same time, the review confirms pouches are considerably less toxic than cigarettes, and evidence suggests pouch use substantially reduces smoking among daily smokers. But the honest caveat is blunt: the studies so far mostly show dual use rather than complete cigarette cessation, and long-term health outcomes remain understudied. Lower toxicant exposure is not the same as no risk.

Why it matters

This is the evidence base that both sides of the regulation fight will quote. Harm-reduction advocates now have a current, publicly funded review confirming pouches expose users to far fewer toxicants than smoking. Restriction advocates have the youth-use uptick, the tripling sales curve and the youth-appealing marketing finding in the same document. Both are accurately describing it.

For regulators drafting rules right now — Spain's decree, the EU's TPD consultation, Ireland's bill — the practical takeaway is that the old excuse of "we don't have enough research to regulate intelligently" is getting weaker with every review cycle. What's still missing is the research that takes the longest: years of follow-up on people who use pouches long-term, and better data on whether pouches ultimately move people off cigarettes or just layer nicotine on top.

If you want to see what the products these studies measure actually look like in the market, compare pouch brands and strengths at PouchFinder.

SOURCES